Who Paid My Doc
Mohammed Nisar
Edison, NJ Medical Doctor
NPI 1124114343 CMS profile 278420
1895 Oak Tree Rd, Edison, NJ 08820
General payments
$43
Research payments
$2,214
Ownership & investment interest
$0
Research they led as principal investigator
$2,568,012
Through program year 2025, Mohammed Nisar of Edison, NJ is reported in the CMS Open Payments database as having received $43 across 3 general payments and $2,214 in research payments paid to them. Separately, studies naming them as principal investigator received $2,568,012 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | Research | $2,214 | 2 | |
| 2020 | General | $14 | 1 | |
| 2019 | General | $30 | 2 |
Beside peers
- Mohammed Nisar
- New Jersey median
- Middle half of New Jersey
- National median
In program year 2025, general payments to Mohammed Nisar were reported at $0. Among 31,834 New Jersey profiles paid that year, the median was $178 and the middle half received between $51 and $585.
Show as a table
| Year | Mohammed Nisar | New Jersey median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $30 | $150 | $44–$542 | $163 |
| 2020 | $14 | $110 | $33–$349 | $114 |
| 2021 | $0 | $125 | $36–$419 | $132 |
| 2022 | $0 | $142 | $42–$480 | $149 |
| 2023 | $0 | $156 | $48–$510 | $160 |
| 2024 | $0 | $167 | $50–$562 | $164 |
| 2025 | $0 | $178 | $51–$585 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 39 drugsPart D claims
816
Drug cost
$99,977
Branded share of claims
20.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Evenity (2 Syringes) Romosozumab-Aqqg | Brand | 11 | $26,473 | |
| Lupron Depot Leuprolide Acetate | Brand | 12 | $23,812 | |
| Xarelto Rivaroxaban | Brand | 14 | $14,049 | |
| Linzess Linaclotide | Brand | 15 | $12,312 | |
| Diclofenac Sodium | Generic | 13 | $9,585 | |
| Colchicine | Generic | 14 | $1,453 | |
| Atorvastatin Calcium | Generic | 101 | $1,259 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 20 | $1,145 | |
| Valsartan-Hydrochlorothiazide Valsartan/Hydrochlorothiazide | Brand | 19 | $1,042 | |
| Metoprolol Succinate | Generic | 29 | $724 |
The 10 drugs with the highest cost, of 39 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 35 billing codesPaid by Medicare
$52,701
Medicare patients
47
Services billed
2,736
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 43% | |
| Arthritis | 38% | |
| Ischemic heart disease | 30% | |
| Chronic kidney disease | 26% | |
| Osteoporosis | 26% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90662 | Office | 15 | 15 | $662 |
| Infusion, normal saline solution, 250 cc J7050 | Office | 14 | 135 | $68 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.